secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-039123
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics shareholders approve increase in authorized shares to 425M
-------------------------------------------------------------------------------

- Authorized common stock increased from 325M to 425M shares; approved by 201.9M votes for vs 10.0M against.
- Three Class I directors elected: Yezan Haddadin, Kurt J. Hilzinger, Faisal G. Sukhtian (each >154M votes for).
- Shareholders approved potential issuance >19.99% of outstanding upon conversion of convertible note (151.0M for).
- KPMG ratified as auditor for FY ending Sep 30, 2023 (213.0M for); say-on-pay approved (149.5M for).
- Annual meeting turnout: 213.8M shares present (83.28% of outstanding).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923039123/0001104659-23-039123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923039123/tm2311019d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-039123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer